TP53 and lung carcinoma: In lung cancer, this activity is strengthened by mut-p53- dependent induction of co-inhibitory ligands (such as PD-L1), that further constrain T cell activity upon MHC-I peptide recognition, an activity observed for a wide spectrum of missense TP53 mutations (82).